Novartis Print Subway Commuter Unicorn by Harrison & Star New York

Adsarchive » Print ads » Novartis » Subway Commuter Unicorn

Subway Commuter Unicorn

Pin to Collection
Add a note
Industry Health & Pharmaceutical Products
Media Print, Magazine & Newspaper
Market United States
Agency Harrison & Star New York
Creative Director Mark Friedman, Mike Norkin, Dean Szostczuk, Josh Eastman
Art Director Matt Lee, Dean Szostczuk, Donna Tedesco, Matt Kemler
Copywriter Josh Eastman, Garrett Allen, Brian McCoy
Released November 2017

Credits & Description

Category: Pharmaceutical
Media: Print
Brand: Novartis
Agency: Harrison and Star
Geo: United States
Advertising Agency: Harrison And Star/Omnicom, New York, USA
Creative Directors: Mark Friedman, Mike Norkin, Dean Szostczuk, Josh Eastman
Art Directors: Dean Szostczuk, Matt Lee, Donna Tedesco, Matt Kemler
Copywriters: Josh Eastman, Garrett Allen, Brian McCoy
Photographer: Vincent Dixon
Digital Artists: Clive Biley, David Brungard, James Cullinane
Published: November 2017
For the past 30 years, a diagnosis of acute myeloid leukemia (AML) has been a death sentence for many patients. Unlike most other forms of cancer, treatment advances have been few and far between, and an archaic chemo cocktail remains the decades-long standard of care. This has lead to the worst 5-year survival rate of any form of adult leukemia, and the hope for long-term survival little more than wishful thinking.
Now with Rydapt, the future has become brighter. As the first targeted agent approved in decades, patients will finally experience the benefit of sustained survival benefits. The Unicorn, embedded in everyday scenarios like the subway, represents how the myth of extended survival is finally a reality in AML.
Make the Myth of Extended Survival a Reality
Introducing RYDAPT, a treatment for adults with newly diagnosed FLT3+ AML eligible for intensive chemotherapy